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Summary: Plasma poly amines (spermidine and spermine) and diamines (diaminopropane, putrescine, and cadaverine)
were determined after cold acid extraction of the blood plasma of patients suffering from severe liver insufficiency.
Correlations were made with liver function tests, i.e. cholinesterase activity and normotest, a global test for the
ability of the liver to synthesize the blood clotting factors II, VII and X. The plasma polyamine levels of patients
were compared with those of a normal population.
Relevant statistical approaches demonstrated a normal distribution of the values for the healthy control group and an
abnormal distribution in the diseased group. Within both groups the polyamines were found to be mutually linearly
correlated with the exception of the putrescine — spermine pair in the normals and the diaminopropane/spermine pair
in the patients.
A comparison between the diseased and healthy groups demonstrated significant elevations of putrescine, cadaverine,
and spermidine in the former. In 78% of the patients, at least one of the polyamines was found to be abnormally elevated,
whereas no elevations whatsoever were observed in 22% of the cases. Putrescine, at concentrations up to 3 / , and
cadaverine up to 6 / showed the highest elevations in comparison to normals (85.3 ± 35.3 nmol/1 for putrescine
and lower than 20 nmol/1 for cadaverine). Spermidine, spermine and diaminopropane concentrations reached concen-
trations of approximately 1 >1/1, 500 nmol/1 and 150 nmol/1, compared with the mean normal values of 94.6 ± 34.5
nmol/1, 39.8 ± 29.2 nmol/1, and 16.9 ± 9.31 nmol/1, respectively. In patients, cadaverine is inversely correlated with the
liver normotest, and spermine is directly correlated with cholinesterase activity. Liver involvement is discussed with
regard to the Value of polyamine levels as tumour markers. No definite conclusions can be drawn as to the cause of the
polyamine elevations found in liver-diseased patients.
Der Polyamingehalt des Blutplasmas von Patienten mit Leberschaden
Zusammenfassung: Der Gehalt der Polyamine Spermidin uiid Spermin sowie der Diamine Diaminopropan, Putrescin
und Cadaverin wurde nach Extraktion mit kalter Säure im Blutplasma von Patienten mit schwerer Leberinsuffizienz
bestimmt. Zusammenhänge mit Ergebnissen von Leberfunktionspriifungen wurden hergestellt, nämlich mit Cholinester-
aseaktivität und dem Normotest, einem umfassenden Test für die Fähigkeit der Leber, die Gerinnungsfaktoren II, VII
und X zu bilden. Die Patienten würden außerdem hinsichtlich ihres Polyamingehaltes mit einer gesunden Population
verglichen.
Das statistische Verfahren zeigte eine normale Verteilung für die Werte der gesunden Kontrollgruppe und eine abnor-
male Verteilung in der erkrankten Gruppe. Gefunden wurde, daß innerhalb beider Gruppen die Polyamine mitein-
ander korrelieren mit Ausnahme des Putrescin/Sperminpaares in der Kontrollgruppe und des Diaminopropan/Spermin-
paares bei den Patienten. Vergleiche zwischen der erkrankten und der gesunden Gruppe zeigten signifikante Erhöhungen
von Putrescin, Cadaverin und Spermin in der ersteren. Bei. 78% der Patienten war mindestens bei einem Polyamin die
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Konzentration abweichend, während in 22% der Fälle überhaupt keine Erhöhung beobachtet wurde; indem sie
Putrescin-Konzentrationen bis zu 3 jumol/1 and Cadaverin bis zu 6 /l erreichen, zeigen sie die größte Erhöhung im
Vergleich zur Normalgruppe (85,3 ± 35,3 nmol/1 für Putrescin, beziehungsweise weniger als 20 nmol/1 für Cadaverin).
Die Konzentrationen von Spermidin, Spermin und Diaminopropan erreichen annähernd Werte von l / , 500
nmol/1 und 150 nmol/1 im Vergleich zu den Mittelwerten der Normalgruppe von 94,6 ± 34,5 nmol/1, 39,8 ± 29,2
nmol/1, beziehungsweise 16,9 ± 9,31 nmol/1. Es wird gezeigt, daß Cadaverin bei den Patienten indirekt korreliert mit
den Leber-Normotestwerten und Spermin direkt korreliert mit der Cholinesteraseaktivität. Die Leberbeurteilung
wurde in Bezug auf den Wert der Polyamingehalte als Tumormarker diskutiert. Keine endgültigen Schlüsse können
über die Ursache der Erhöhungen der Polyamine in der Leber der Patienten gezogen werden.
Introduction
Biogenic amines are formed by decarboxylation of
amino acids. Some are biologically very active, playing
important roles as neurotransmitters (y-aminobutyric
acid, dopamine, serotonine), or as hormone precursors
(adrenaline, thyroxine, melatonin), or as components
of coenzymes (propanolamine, cysteamine, ß-alanine)
(1). During recent years, increased interest has been
shown in aliphatic biogenic amines, designated poly-
amines. They include putrescine, spermidine, and
spermine, which originate from their amino acid pre-
cursors ornithine and methionine. Also of biological
importance are their homologues, cadaverine (most
likely originating from lysine) and diaminopropane
(2-7).
It is known that polyamines are found in all living cells
and are deaminated by a heterogeneous group of poly-
and di-amino-oxidases (8—13). Furthermore, their
degradation by oxidation following acetylation, has
been shown to occur in brain and liver in vivo (14-16).
Rosenblum & Rüssel (17) directed attention to the
importance of covalent bonding of the polyamines to
macromolecular structures.
Our primary interest in this study is based on the
observation that biosynthesis of polyamines increases
in rapidly proliferating cells (2-10, 12-13). Poly-
amine determinations in biopsy material, as well as
in body fluids has been suggested as a monitor for
the progress of tumour patients (5, 8, 18-20). The
specificity of the polyamines as tumour markers was
shown, however, to be limited, because their concen-
trations vary under physiological conditions. Polyamine
concentrations are, for instance, influenced by age,
sex, diet and pregnancy (18). Some non-malignant ·
diseases affect polyamine serum and urine concentra-
tions to an even higher degree, i.e. uraemia, athero-
sclerosis, polycythaemiavera, cystic fibrosis, psoriasis,
infections etc. (reviewed in I.e. 5, 8, 18). Little is known
about the influence of liver diseases on polyamine
metabolism. A few investigators have observed that
some patients with hepatitis, cirrhosis of the liver, and
liver abscesses have high polyamine concentrations in
serum or urine (21-26). To our knowledge, systematic
investigations have not been carried out. In experi-
mental animals, it has been shown that changes in liver
function and regeneration (toxin action, hepatectomies,
chemically induced carcinogenesis) leads to changes in
polyamine concentration in this organ (8, 18, 27-35).
Therefore, with changes in liver function, a change in
polyamine concentrations in serum and/or urine can
be expected.
In the following investigation, the concentration of
polyamines in the blood of patients with liver» diseases
was correlated with the severity of the disturbed liver
function, as defined by the normotest and by plasma
cholinesterase activities.
Materials and Methods
The study included 64 untreated patients with severe liver
diseases (61% men, 39% women), aged 10 to 73 years with
normotest values below 50% (normal range: 70-100%) and/or
with cholinesterase activity under 1.0 kU/1 (normal range:
2.5-3.5 kU/1). Liver insufficiency was due to acute liver
failure (17 patients), cirrhosis with hepatic coma (18 patients),
cirrhosis with hepatic coma (18 patients), cirrhosis without
hepatic coma (17 patients), and a mixed population consisting
of patients with hepatitis, shock liver or sepsis (12 patients).
Patients with malignancies were excluded from this study.
The blood plasma of 20 healthy volunteers aged 26 to 39,
average age of 32.8 ± 4.8 years, of which 70% were males and
30% females, were utilized as controls. The study was con-
ducted with approval of the Ethics and Research Committees
of the General Hospital of Vienna.
Sample preparation
Immediately after admission, blood samples were taken at room
temperature from liver diseased patients into heparinized tubes,
and the plasma was frozen at -20 °C until further handling.
In preparation for analysis of polyamines, 33 g/1 5-sulfosalicylic
acid in 0.1 mol/1 HC1 was added to deproteinize the plasma and
left to stand for 30 min at 0 °C The resulting suspension was
centrifuged at 3000 £ for 10 min. The precipitate was washed
twice with 3 g/15-sulfosalicylic acid in 0.1 mol/1 HCL The
supernatants were collected and freeze dried. The residues were
dissolved ino1.5 ml 0.1 mol/1 HC1 and centrifuged for 2.5 min at
15 000 g. Samples of 300 were applied to the Chromatograph
for separation.
Analytical procedure
For separation of polyamines, a strongly acidic cation-exchange
resin was employed. A fluorescence detector was used for
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measurement of the primary diamines after reaction with
o-phthalaldehyde. The procedure has been described in detail
elsewhere (36). Identity of the diaminopropane peak has not
yet been determined with certainty. Cochromatograms of
physiological samples with a diaminopropane test solution,
however, indicated good agreement of retention times and con-
gruence of peaks. Normotest, which measures blood clotting
factors II, VII and X as piotrombin time (37-38), and cholin-
esterase activity obtained through the established butyrylthio-
choline method (39) show good correlation with liver dys-
function (37-38).
Statistics
Data were submitted to the following statistical tests at the
computer center of the University of Veterinary Medicine:
1. Test for normal distribution applying the Kolomogorov·
Smirnov method (40).
2. Calculation of correlation between variables within the
disease group and within the healthy population according to
Kendall (40).
3. Comparison between patients and the normal population
by means of the U-paired rank classification test after Mann-
Whitney-Wilcoxon (40).
Individual values are defined as increased if they exceed the
mean value of the control group by more than 2 times standard
deviation.
Tab. 1. Polyamine content of plasma from normal subjects in
nmol/1.
Diamino-
propane
Putrescine
Cadaverine
Spermidine
Spermine
÷ s
16.85 ± 9.31
85.25 ± 35.33
0 [< 20]
94.60 ±34.50
39.80 ± 29.24
(n)
(20)
(20)
(20)
(20)
(20)
Mini-
mum
Ö
47.00
Ö
48.00
Ö
Maxi-
mum
35.00
178.00
Ö
158.00
110.00
÷ ± s (n) = mean ± standard deviation (number of cases)
ö = not detectable
propane/spermine pair, were found to be correlated.
Furthermore, cadaverine which, in contrast to normals,
was frequently found in patients, was also found to be
correlated with the other polyamines. Cadaverine was
also found to be inversely correlated to values of the
liver normotest, whereas spermine was calculated to be
dependent on cholinesterase activity.
The comparison between the normal and diseased group
is shown in table 3. This comparison had to be calculated
Results
In table 1 the mean values of polyamines in the normal
population are shown. Statistical evaluation of the data
of this group revealed the existence of a normal distribu-
tion for the variables.
Within the normal and within the diseased group,
resulting correlations are displayed in table 2. In the
normal group all polyamine pairs were found to be cor-
related, with the exception of the putrescine/spermine
pair. In patients, all pairs, with exception of the diamino-
Tab. 3. Comparison of polyamine content in the plasma of
healthy and diseased subjects. Rank average value*.
Diaminopropane
Putrescine
Cadaverine
Spermidine
Spermine
Normals
39.4(20)
21.5 (20)
28.0 (20)
26.6 (20)
43.2(20)
Patients
37.5 (55)
49.1 (64)
47.0 (64)
46.9 (63)
39.5 (60)
Ñ
n. s.
< 0.001
< 0.001
<0.01
n. s.
n.s.: not significant
* U-Test according to Wilcoxon (number of cases)
Tab. 2. Dependence of the variables among each other in the normal group and in the disease group.
Diamino-
propane
Putrescine Cadaverine Spermidine Spermine Cholin-
esterase
Normotest
Diaminopropane
Putrescine
Cadaverine
Spermidine
Spermine
Cholinesterase
0.3360*
(20)
0.3617*
(20)
0.4216*
(20)
§0.2928*
(55)
0.4085*
(20)
0.2426
(20)
Diseased
0.2147* 0.2706*
(55)
0.4209*
(64)
(54)
0.4112*
(63)
0.3341*
(63)
0.3764*
(20)
0.0647
(51)
0.2629*
(60)
0.2886*
(60)
0.1884*
(59)
-0.1138
(51)
0.0823
(60)
0.0765
(60)
0.1088
(59)
0.2256*
(57)
- 0.0484
(54)
-0.0323
(63)
-0.1788*
(63)
-0.1583
(62)
0.1192
(59)
0.0278
(60)
Normal
§: Correlation coefficient (number of data pairs).
*: significant correlation p < 0.05.
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by the Mann-Whtiney-U-Wilcoxon rank classification test,
since data obtained in the diseased group were found to be
abnormally distributed. Significant differences between
diseased and healthy populations were observed in plasma
polyamine concentrations for putrescine (p < 0.001),
cadaverine (p < 0.001), and spermidine (p < 0.01). In
contrast, diaminopropane and spermine concentrations in
both groups were not distinguishable.
In 51 out of 64 patients, we were able to obtain the
complete profile of all 5 polyamines in each patient. The
distribution frequency of elevated values vs. norm were
found to be as follows: In 22% of patients, no polyamines
were found to be elevated. All 5 polyamines were elevated
in about 4% of the cases, 4 in 10%, 3 in 14%, 2 in 39%,
and 1 in 22%, respectively.
Regarding the incidence of elevations of individual poly-
amines, 14% of all patients had elevated diaminopro-
pane concentrations, 59% elevated putrescine concentra-
tions, 43% elevated spermidine concentrations, 10%
elevated spermine concentrations, and 37% elevated
cadaverine concentrations in their plasma.
The scattergram (fig. 1) demonstrates extent and
relative distribution of amine levels in plasma of diseased
and healthy persons. Especially putrescine and cada-
verine exhibit extremely high values in some patients,
reaching 30 times the norm for putrescine and 300 times
the norm for cadaverine, corresponding to a putrescine
concentration of approximately 3 ìéçïÀ/l and a cadaverine
concentration of approximately 6 ìéçïÀ/À. Spermidine
and spermine occasionally reached levels 10 times higher
than normal; diaminopropane was found in one case to
be 8 times above normal, but in all other cases they did
not exceed 5 times the norm.
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Discussion
The normal distribution for polyamine values in the
control group (Kolmogorov-Smirnov test) is an indication
for a homogenous population. On the other hand, poly-
amine values of the diseased group show an abnormal
distribution.
In general, it has been established that the concentra-
tion of the polyamines in the blood plasma of liver-
diseased persons is frequently elevated compared to the
concentration found in healthy persons. Particularly
putrescine and cadaverine concentrations are increased
to such an extent (scattergram, fig. 1) that they con-
siderably exceed the values found in other pathological
conditions (5, 8, 18). As can be seen, spermidine concen-
trations are also frequently found to be elevated, the
extent of increase also being of importance. Although
the mean spermine value of the diseased group (tab. 3) *
is not significantly different from the mean of the normal
Fig. 1. Scattergram, showing increase in polyamine values
compared to the reference range.
Average of the reference set = 1.
Sensitivity limit for cadaverine = 20 nmol/1.
Number of values below the sensitivity level as number
on the abscissa.
Values framed show the reference range (÷ ± 2 s).
group, cases were occasionally observed with highly
elevated levels for this polyamine too. Diaminopropane
values are less noteworthy.
In addition, inverse correlation of the cadaverine con-
centration with the values of normotest is of special
interest, as this test corresponds to the extent of disturb-
ance in liver function (37-38). The empirically deduced
formula for the relationship in this case is: cadaverine =
-5,9 ÷ nofmotest + 380 (63 data pairs). This means that
cadaverine will probably be detected in plasma of patients
whose normotest value is found to be below 64%; alter-
natively expressed, with normotest values below 10%,
cadaverine will be expected to attain concentrations
higher than 300 nmol/1.
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Although for putrescine, spermidine and spermine no
significant dependence on normotest was calculable,
a remarkable tendency towards an inverse relationship
is observed.
The statistically recognized correlation between spermine
content and cholinesterase activity is a further indication
for relevance of polyamine levels in liver-diseased persons,
since it is known that cholinesterase activity is indicative
of the degree of liver malfunction in patients with liver
disease.
Regarding the variability in polyamine values (scatter-
gram, fig. 1) it seems unlikely however that polyamine
assays can be reliable indicators of liver dysfunction.
Differentiation of the patient population into diagnosti-
cally defined subgroups of liver insufficiences and
recomparison of the quoted variables will certainly
reveal a finer picture. An expanded study involving more
patients would have to be undertaken to achieve this.
The frequency with which increases in a particular
polyamine value occurred did not exceed 60%, e.g. for
putrescine. In 51 patients, for whom all variables were
accessible, a hypernormal value of at least one investi-
gated polyamine was exhibited with a frequency of 78%.
Only 22% of patients showed no increase in any poly-
amine level whatsoever.
Regarding the discussed possibility of using polyamine
profiles as a tumour marker (5, 8, 10, 18), it is important
to take into consideration that, with eventual liver in-
volvement, changes in obtained polyamine values can be
expected. This restricts the specificity of polyamine
determinations for tumour diagnosis. Therefore, in
evaluating polyamine levels in patients with malignant
diseases, this fact must be taken into account. Never-
theless, the observation of changes in polyamine levels
in individual patients is a valuable supplement to clinical
evaluation of the patient's progress and the success of
therapy (8, 18).
Within our normal group, a correlation between all the
specified polyamines was observed with the exception
of the putfescine/spermine pair, where no linear mathe^
matical dependence in blood plasma could be found. On
the other hand, in patient's plasma, all paired poly-
amine values were found to be correlated with exception
of the diaminopropane/spermine pair.
Our data demonstrate that the concentrations of the
polyamines in patients with liver disease are subject to
great changes in comparison to normal controls. In con-
trast, the quotient of paired polyamine concentrations
among sick and among healthy people are in general not
significantly distinguishable. From the data obtained,
it can therefore not be concluded that polyamine meta-
bolism in liver-diseased persons is pathologically dis-
turbed.
In this investigation, the polyamine content was deter-
mined after cold acid extraction. This method frees poly-
amines that are not covalently bound, either to macro-
molecules, or in the form of low molecular weight
derivatives, e.g. acetylated amines. The liver is most
likely a privileged site for polyamine metabolism (8-11,
41). Since acetylation is an important step in poly-
amine catabolism (14-15) it might be possible to show
that a change in the relationship between acetylated
and non-acetylated polyamines occurs in our liver-
diseased patients, with the reservation that with further
catabolism of the acetylated polyamines, the pattern
would be changed again. To date, it has not been possible
for us to test this hypothesis by determinations of cova-
lently and non-covalently bound polyamines directly.
An analytical procedure to this end is at present being
developed. On the other hand, it is possible to examine
polyamine concentrations before and after hot acid
hydrolysis in order to obtain an idea of extent of
covalent bonding present. Furthermore, it would be of
value to investigate enzyme activities involved in poly-
amine catabolism in experimental animals with esta-
blished liver damage.
Using cold acid extraction, we have shown that diamino-
propane, cadaverine, putrescine, spermidine, and spermine
are frequently elevated in the plasma of patients with
severe liver damage as compared to normal persons. It
has not been determined whether these pathological
increases are a result of release of existing endogenous
polyamines from disturbed liver cells or from an accumu-
lation of metabolites as a result of blockade of catabolism
of inherant or exogenous material. It can be assumed
that both mechanisms occur concurrently. This could
be tested in experimental animals and with a mathe-
matical model. In humans, it would be of value to
compare the extent of the pathological polyamine
aberration along with a detailed differential diagnostic
description of patients.
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